Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) in HIV-1/Hepatitis B Coinfected Adults

Joel Gallant, Jason Brunetta, Gordon Crofoot, Paul Benson, Anthony Mills, Cynthia Brinson, Shinichi Oka, Andrew Cheng, Will Garner, Marshall Fordyce, Moupali Das, Scott McCallister

Research output: Contribution to journalArticlepeer-review

Abstract

ABSTRACT:: Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) has high efficacy and improved renal and bone safety in multiple Phase 3 trials; TAF single agent is being studied in two Phase 3 trials in chronic hepatitis B patients. We report the results of an open-label, non-comparative switch study evaluating the efficacy and safety of E/C/F/TAF in HIV/HBV-coinfected adults. At 48 wee 91.7% of the 72 participants maintained or achieved virologic suppression (HIV-1 RNA

Original languageEnglish (US)
JournalJournal of Acquired Immune Deficiency Syndromes
DOIs
StateAccepted/In press - May 11 2016
Externally publishedYes

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) in HIV-1/Hepatitis B Coinfected Adults'. Together they form a unique fingerprint.

Cite this